{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:34:53Z","timestamp":1740123293653,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The funder being the subsidy fund for medical service and security capacity improvement of the Central Department of Finance","award":["Z155080000004"],"award-info":[{"award-number":["Z155080000004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s10637-024-01421-7","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T05:21:41Z","timestamp":1705987301000},"page":"116-126","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4185-821X","authenticated-orcid":false,"given":"Meng-Ting","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si-Yong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3514-9086","authenticated-orcid":false,"given":"Ji-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,23]]},"reference":[{"key":"1421_CR1","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40265-022-01723-1","volume":"82","author":"J Paik","year":"2022","unstructured":"Paik J (2022) Nivolumab plus Relatlimab: first approval. Drugs 82:925\u2013931","journal-title":"Drugs"},{"key":"1421_CR2","doi-asserted-by":"crossref","unstructured":"Vaddepally RK, Kharel P, Pandey R et al (2020) Review of indications of fda-approved immune checkpoint inhibitors per nccn guidelines with the level of evidence. Cancers (Basel) 12","DOI":"10.3390\/cancers12030738"},{"key":"1421_CR3","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.annonc.2020.11.016","volume":"32","author":"T Powles","year":"2021","unstructured":"Powles T (2021) clinicalguidelines@esmo.org EGCEa. Recent eupdate to the esmo clinical practice guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: renal cell carcinoma: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 32:422\u2013423","journal-title":"Ann Oncol"},{"key":"1421_CR4","doi-asserted-by":"publisher","first-page":"k4226","DOI":"10.1136\/bmj.k4226","volume":"363","author":"C Xu","year":"2018","unstructured":"Xu C, Chen YP, Du XJ et al (2018) Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ 363:k4226","journal-title":"BMJ"},{"key":"1421_CR5","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML et al (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375:1749\u20131755","journal-title":"N Engl J Med"},{"key":"1421_CR6","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","volume":"89","author":"S Suzuki","year":"2017","unstructured":"Suzuki S, Ishikawa N, Konoeda F et al (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89:1127\u20131134","journal-title":"Neurology"},{"key":"1421_CR7","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV et al (2018) Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71:1755\u20131764","journal-title":"J Am Coll Cardiol"},{"key":"1421_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","volume":"20","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi A, Ribas A (2020) Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol 20:25\u201339","journal-title":"Nat Rev Immunol"},{"key":"1421_CR9","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1161\/CIRCRESAHA.115.306573","volume":"118","author":"G Fung","year":"2016","unstructured":"Fung G, Luo H, Qiu Y et al (2016) Myocarditis Circ Res 118:496\u2013514","journal-title":"Myocarditis Circ Res"},{"key":"1421_CR10","doi-asserted-by":"publisher","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","volume":"18","author":"JA Thompson","year":"2020","unstructured":"Thompson JA, Schneider BJ, Brahmer J et al (2020) Nccn guidelines insights: management of immunotherapy-related toxicities, version 1.2020. J Natl Compr Canc Netw 18:230\u2013241","journal-title":"J Natl Compr Canc Netw"},{"key":"1421_CR11","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","volume":"23","author":"S Ganatra","year":"2018","unstructured":"Ganatra S, Neilan TG (2018) Immune checkpoint inhibitor-associated myocarditis. Oncologist 23:879\u2013886","journal-title":"Oncologist"},{"key":"1421_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000247","volume":"2","author":"G Varricchi","year":"2017","unstructured":"Varricchi G, Galdiero MR, Marone G et al (2017) Cardiotoxicity of immune checkpoint inhibitors. ESMO Open 2:e000247","journal-title":"ESMO Open"},{"key":"1421_CR13","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M et al (2018) Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 19:1579\u20131589","journal-title":"Lancet Oncol"},{"key":"1421_CR14","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi JJ, Salem JE, Sosman JA et al (2018) Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391:933","journal-title":"Lancet"},{"key":"1421_CR15","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/14740338.2021.1906860","volume":"20","author":"R Poto","year":"2021","unstructured":"Poto R, Marone G, Pirozzi F et al (2021) How can we manage the cardiac toxicity of immune checkpoint inhibitors? Expert Opin Drug Saf 20:685\u2013694","journal-title":"Expert Opin Drug Saf"},{"key":"1421_CR16","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/ehjci\/jeaa339","volume":"22","author":"C Zito","year":"2021","unstructured":"Zito C, Manganaro R, Cusma Piccione M et al (2021) Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the working group on drug cardiotoxicity and cardioprotection, Italian society of cardiology (sic). Eur Heart J Cardiovasc Imaging 22:406\u2013415","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"1421_CR17","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10549-011-1783-9","volume":"133","author":"C Fedele","year":"2012","unstructured":"Fedele C, Riccio G, Coppola C et al (2012) Comparison of preclinical cardiotoxic effects of different erbb2 inhibitors. Breast Cancer Res Treat 133:511\u2013521","journal-title":"Breast Cancer Res Treat"},{"key":"1421_CR18","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1089\/ars.2019.7842","volume":"31","author":"V Mercurio","year":"2019","unstructured":"Mercurio V, Cuomo A, Della Pepa R et al (2019) What is the cardiac impact of chemotherapy and subsequent radiotherapy in lymphoma patients? Antioxid Redox Signal 31:1166\u20131174","journal-title":"Antioxid Redox Signal"},{"key":"1421_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-019-0535-y","volume":"7","author":"M Awadalla","year":"2019","unstructured":"Awadalla M, Golden DLA, Mahmood SS et al (2019) Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. J Immunother Cancer 7:53","journal-title":"J Immunother Cancer"},{"key":"1421_CR20","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/s41581-018-0035-1","volume":"14","author":"K Sury","year":"2018","unstructured":"Sury K, Perazella MA, Shirali AC (2018) Cardiorenal complications of immune checkpoint inhibitors. Nat Rev Nephrol 14:571\u2013588","journal-title":"Nat Rev Nephrol"},{"key":"1421_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","volume":"22","author":"EP Darnell","year":"2020","unstructured":"Darnell EP, Mooradian MJ, Baruch EN et al (2020) Immune-related adverse events (iraes): diagnosis, management, and clinical pearls. Curr Oncol Rep 22:39","journal-title":"Curr Oncol Rep"},{"key":"1421_CR22","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/cas.12961","volume":"107","author":"T Kimura","year":"2016","unstructured":"Kimura T, Fukushima S, Miyashita A et al (2016) Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci 107:1055\u20131058","journal-title":"Cancer Sci"},{"key":"1421_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13256-022-03286-x","volume":"16","author":"Y Saishu","year":"2022","unstructured":"Saishu Y, Yoshida T, Seino Y et al (2022) Nivolumab-related myasthenia gravis with myositis requiring prolonged mechanical ventilation: a case report. J Med Case Rep 16:61","journal-title":"J Med Case Rep"},{"key":"1421_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11886-017-0870-x","volume":"19","author":"ALP Caforio","year":"2017","unstructured":"Caforio ALP, Malipiero G, Marcolongo R et al (2017) Myocarditis: a clinical overview. Curr Cardiol Rep 19:63","journal-title":"Curr Cardiol Rep"},{"key":"1421_CR25","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s00432-019-02927-x","volume":"145","author":"SA Atallah-Yunes","year":"2019","unstructured":"Atallah-Yunes SA, Kadado AJ, Kaufman GP et al (2019) Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases. J Cancer Res Clin Oncol 145:1527\u20131557","journal-title":"J Cancer Res Clin Oncol"},{"key":"1421_CR26","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jacc.2011.09.074","volume":"59","author":"I Kindermann","year":"2012","unstructured":"Kindermann I, Barth C, Mahfoud F et al (2012) Update on myocarditis. J Am Coll Cardiol 59:779\u2013792","journal-title":"J Am Coll Cardiol"},{"key":"1421_CR27","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s40425-018-0473-0","volume":"6","author":"C Monge","year":"2018","unstructured":"Monge C, Maeng H, Brofferio A et al (2018) Myocarditis in a patient treated with nivolumab and prostvac: a case report. J Immunother Cancer 6:150","journal-title":"J Immunother Cancer"},{"key":"1421_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01350","volume":"10","author":"YW Zhou","year":"2019","unstructured":"Zhou YW, Zhu YJ, Wang MN et al (2019) Immune checkpoint inhibitor-associated cardiotoxicity: current understanding on its mechanism, diagnosis and management. Front Pharmacol 10:1350","journal-title":"Front Pharmacol"},{"key":"1421_CR29","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/science.291.5502.319","volume":"291","author":"H Nishimura","year":"2001","unstructured":"Nishimura H, Okazaki T, Tanaka Y et al (2001) Autoimmune dilated cardiomyopathy in pd-1 receptor-deficient mice. Science 291:319\u2013322","journal-title":"Science"},{"key":"1421_CR30","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.4049\/jimmunol.181.4.2513","volume":"181","author":"JA Lucas","year":"2008","unstructured":"Lucas JA, Menke J, Rabacal WA et al (2008) Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in mrl mice. J Immunol 181:2513\u20132521","journal-title":"J Immunol"},{"key":"1421_CR31","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/intimm\/dxq026","volume":"22","author":"J Wang","year":"2010","unstructured":"Wang J, Okazaki IM, Yoshida T et al (2010) Pd-1 deficiency results in the development of fatal myocarditis in mrl mice. Int Immunol 22:443\u2013452","journal-title":"Int Immunol"},{"key":"1421_CR32","doi-asserted-by":"publisher","first-page":"721333","DOI":"10.3389\/fcvm.2021.721333","volume":"8","author":"R Rikhi","year":"2021","unstructured":"Rikhi R, Karnuta J, Hussain M et al (2021) Immune checkpoint inhibitors mediated lymphocytic and giant cell myocarditis: uncovering etiological mechanisms. Front Cardiovasc Med 8:721333","journal-title":"Front Cardiovasc Med"},{"key":"1421_CR33","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1361097","volume":"6","author":"A Reuben","year":"2017","unstructured":"Reuben A, Petaccia de Macedo M, McQuade J et al (2017) Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. Oncoimmunology 6:e1361097","journal-title":"Oncoimmunology"},{"key":"1421_CR34","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/bjc.2017.253","volume":"117","author":"RY Tay","year":"2017","unstructured":"Tay RY, Blackley E, McLean C et al (2017) Successful use of equine anti-thymocyte globulin (atgam) for fulminant myocarditis secondary to nivolumab therapy. Br J Cancer 117:921\u2013924","journal-title":"Br J Cancer"},{"key":"1421_CR35","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.cjca.2018.03.007","volume":"34","author":"S Yamaguchi","year":"2018","unstructured":"Yamaguchi S, Morimoto R, Okumura T et al (2018) Late-onset fulminant myocarditis with immune checkpoint inhibitor nivolumab. Can J Cardiol 34:812. e811-812 e813","journal-title":"Can J Cardiol"},{"key":"1421_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.851032","volume":"10","author":"N Rubio-Infante","year":"2022","unstructured":"Rubio-Infante N, Ram\u00edrez-Flores YA, Castillo EC et al (2022) A systematic review of the mechanisms involved in Immune checkpoint inhibitors Cardiotoxicity and challenges to improve clinical safety. Front Cell Dev Biol 10:851032","journal-title":"Front Cell Dev Biol"},{"key":"1421_CR37","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L et al (2022) Management of toxicities from immunotherapy: Esmo clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 33:1217\u20131238","journal-title":"Ann Oncol"},{"key":"1421_CR38","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 36:1714\u20131768","journal-title":"J Clin Oncol"},{"key":"1421_CR39","doi-asserted-by":"publisher","first-page":"807","DOI":"10.7326\/0003-4819-138-10-200305200-00008","volume":"138","author":"HJ Kwon","year":"2003","unstructured":"Kwon HJ, Cote TR, Cuffe MS et al (2003) Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 138:807\u2013811","journal-title":"Ann Intern Med"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01421-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-024-01421-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01421-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T10:07:51Z","timestamp":1708682871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-024-01421-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,23]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1421"],"URL":"https:\/\/doi.org\/10.1007\/s10637-024-01421-7","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2024,1,23]]},"assertion":[{"value":"23 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not require an ethical board approval because the study was a retrospective study and did not involve sensitive personal information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}